Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients

Table 4 Factors at 24 wk influencing hepatitis B e antigen seroconversion in treated patients evaluated using univariate and multivariate analyses n (%)

Parameter	RS	Univariate analysis	P value	Multivariate analysis	P value
		OR (95%CI)		OR (95%CI)
ALT ≤ 1 × ULN	25 (45.5)	2.65 (1.30-5.42)	0.008
HBV DNA ≤ 4 log10 copies/mL	32 (50.8)	4.48 (2.25-10.01)	< 0.001
HBsAg ≤ 2000 IU/mL	33 (52.4)	5.50 (2.58-11.73)	< 0.001
HBeAg ≤ 5 S/CO	41 (65.1)	24.23 (9.11-64.47)	< 0.001	16.82 (5.07-55.79)	< 0.001
anti-HBc > 11.4 S/CO	30 (44.8)	3.01 (1.46-6.18)	0.003	3.01 (1.20-7.56)	0.019
Decline ALT > 2 × ULN	35 (42.2)	3.16 (1.47-6.78)	0.003
Decline HBV DNA > 2 log10 copies/mL	36 (46.8)	4.71 (2.15-10.32)	< 0.001
Decline HBsAg > 1 log10 IU/mL	26 (49.1)	3.35 (1.62-6.91)	0.001
Decline HBeAg > 2 log10 S/CO	30 (66.7)	10.00 (4.45-22.47)	< 0.001	1.85 (0.62-5.49)	0.269
Decline anti-HBc > 0.5 S/CO	19 (47.5)	2.55 (1.20-5.43)	0.015

ALT: Alanine aminotransferase; ULN: Upper limit of normal; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; anti-HBc: Antibody to hepatitis B core antigen; RS: Patients with HBeAg seroconversion.